Search

everythinglearnresearchcommunity

for

Search:↓

Dermastamp is preferred for hair growth and skin health due to fewer scars, with recommended needle sizes of 0.5-1.5mm. Dermapen is also favored over dermarollers, which are considered dangerous.

Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

After gyno surgery, OP is considering restarting finasteride at a lower dose (0.25mg/0.5mg) or switching to topical to reduce the risk of gyno recurrence. Lower doses and topical application may lessen side effects due to reduced systemic absorption.

An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.

The conversation is about using RU58841 for hair loss, with OP currently using topical finasteride. OP is seeking experiences and advice on RU58841.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.